Erlotinib EGFR inhibitors
systematic review meta-analysis network meta-analysis
 

OSI-774 - CP-358774 - CP 358774 - Tarceva      

Select             pdf
Filter

  • Group by...
Trial Studied trt Control trt patientstagsROB Trial resultprogression or death (progression free survival PFS) death (overall survival)

lung cancer (metastatic)  

OPTIMAL     erlotinibPlatinum-based CT EGFR mutations Risk of bias suggesting-84%
EUTRAC     erlotinibPlatinum-based CT 1st line EGFR mutations Risk of bias suggesting-63%
TITAN       erlotinibPlatinum-based CT 2nd line Risk of bias negative-4%
TRIBUTE (Herbst)     erlotinib + Platinum-based CTPlatinum-based CT 1st line negative0%
Gatzemeier     erlotinib + Platinum-based CTPlatinum-based CT 1st line negative-2%
Mok     erlotinib + Platinum-based CTPlatinum-based CT 1st line suggesting-29%9%
SATURN (Cappuzzo)     erlotinib + Platinum-based CTPlatinum-based CT maintenance therapy suggesting-19%
Boutsikou     erlotinib + Platinum-based CTPlatinum-based CT 1st line negative-19%
Lee     erlotinib + Platinum-based CTPlatinum-based CT 2nd line suggesting-42%-25%
Stinchcombe   erlotinib + Platinum-based CTPlatinum-based CTnegative-13%20%
FASTACT-2 (Wu)     erlotinib + Platinum-based CTPlatinum-based CT 1st line suggesting-43%-21%



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons